Clinical Trial Update: Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial comparing low-dose bevacizumab with hypofractionated stereotactic radiotherapy versus bevacizumab alone for recurrent glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Huashan Hospital | Conditions: Glioma, Recurrent Glioma | Phase 2 | Status: UNKNOWN